Anti-mouse CD137 (TNFRSF9 or 4-1BB) Antibody (Clone: LOB12.3) | PA007275.r1
$150.00 – $900.00
Recombinant rat IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
- Details & Specifications
- References
| Catalog No. | PA007275.r1 |
|---|---|
| Product Name | In vivo Grade Recombinant Anti-mouse CD137 (TNFRSF9 or 4-1BB) Monoclonal Antibody (Clone: LOB12.3), Rat IgG1 Kappa |
| Supplier Name | Syd Labs, Inc. |
| Brand Name | Syd Labs |
| Synonyms | cluster of differentiation 137, CD137, TNFRSF9 |
| Summary | The anti-mouse CD137 (TNFRSF9 or 4-1BB) monoclonal antibody (clone: LOB12.3) was produced in mammalian cells. |
| Clone | LOB12.3 |
| Isotype | Rat IgG1 Kappa |
| Specificity/Sensitivity | The in vivo grade recombinant anti-mouse CD137 (TNFRSF9 or 4-1BB) monoclonal antibody (clone: LOB12.3) specifically binds to the mouse 4-1BB protein. |
| Applications | ELISA, flow cytometry, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the mouse 4-1BB protein. |
| Form Of Antibody | 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives. |
| Endotoxin | < 1 EU per 1 mg of the protein by the LAL method. |
| Purity | >95% by SDS-PAGE under reducing conditions and HPLC. |
| Shipping | The in vivo grade recombinant anti-mouse CD137 (TNFRSF9 or 4-1BB) monoclonal antibody (clone: LOB12.3) is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied. |
| Note | Recombinant rat IgG1 isotype control antibody and Recombinant human IgG1 isotype control antibodies are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator. |
| Order Offline | Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Or leave a message with a formal purchase order (PO) Or credit card. |
Description
PA007275.r1: Recombinant Anti-mouse CD137 (TNFRSF9 or 4-1BB) Monoclonal Antibody(Clone: LOB12.3), Rat IgG1 Kappa
The anti-mouse CD137 (TNFRSF9 or 4-1BB) monoclonal antibody (clone: LOB12.3) was produced in mammalian cells.
Background of Anti-mouse CD137 (TNFRSF9 or 4-1BB) Monoclonal Antibody (Clone: LOB12.3)
The LOB12.3 antibody binds to 4-1BB (TNFRSF9 or CD137), one representative TNF receptor family co-stimulatory receptor. The 4-1BB protein is expressed on a wide variety of cell types, including activated T cells, NK cells, DCs, B cells, monocytes, and neutrophils. Anti-4-1BB-induced CD8+ T responses play a dominant role in anti-tumor immunity, such as induction of more effector molecules released from CD8+ T cells, increased proliferation and decreased apoptosis of CD8+ T cells.
References of Anti-Mouse CD137 (4-1BB) Monoclonal Antibody (Clone: LOB12.3)
1. Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity.
Qi, et al. Nat Commun. 2019 May 17;10(1):2141. doi: 10.1038/s41467-019-10084-w. PMID: 31101822; PMCID: PMC6526162
“The co-stimulatory receptor 4-1BB (CD137) is a major target for cancer immunotherapy due to its ability to enhance T cell-mediated anti-tumor responses. … Here, we demonstrate that optimizing the balance between agonistic strength and FcγR binding affinity is critical to maximizing therapeutic efficacy. … These findings suggest a design strategy for developing safer and more effective anti-4-1BB antibodies with minimized systemic toxicities.”
2. Intratumoral activation of 41BB co-stimulatory signals enhances CD8 T cell expansion and modulates tumor-infiltrating myeloid cells.
An, et al. J Immunother Cancer. 2020 Dec;8(2):e001384. doi: 10.1136/jitc-2020-001384. PMID: 33328224; PMCID: PMC7741883
“Intratumoral delivery of 4-1BB (CD137) agonistic antibodies is an attractive approach to restrict immune activation to the tumor microenvironment. … This study shows that localized CD137 activation significantly drives CD8+ T cell expansion and rewires the landscape of tumor-infiltrating myeloid cells. … Consequently, targeting 4-1BB locally represents a highly viable therapeutic avenue to overcome systemic immune-related adverse events.”
3. TCR-independent CD137 (4-1BB) signaling promotes CD8+-exhausted T cell proliferation and terminal differentiation.
Takuya, et al. Cell Rep. 2023 Nov 28;42(11):113354. doi: 10.1016/j.celrep.2023.113354. PMID: 37924248; PMCID: PMC10649891
“CD137 (4-1BB) is typically considered a co-stimulatory molecule that acts in concert with T-cell receptor (TCR) activation. … We demonstrate that TCR-independent CD137 signaling can directly drive the proliferation and terminal differentiation of exhausted CD8+ T cells in chronic viral or tumor settings. … These results reveal a novel role for CD137 agonists in reviving exhausted T-cell populations independently of antigen recognition.”
4. Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity.
Hoves, et al. Clin Cancer Res. 2020 May 15;26(10):2310-2321. doi: 10.1158/1078-0432.CCR-19-3121. PMID: 32156742; PMCID: PMC7141404
“Agonistic antibodies targeting CD137 (4-1BB) have shown powerful antitumor effects in preclinical models, but clinical development has been hindered by severe liver toxicity. … Here, we present a differentiated agonistic antibody that achieves robust antitumor efficacy and eradicates large established tumors. … Crucially, this therapeutic approach avoids systemic hepatotoxicity, establishing a wider therapeutic window for clinical applications.”
5. Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity.
Yuan, et al. Nat Commun. 2017 Dec 22;8(1):2248. doi: 10.1038/s41467-017-02484-8. PMID: 29273763; PMCID: PMC5750237
“Systemic administration of immunostimulatory monoclonal antibodies, such as those targeting 4-1BB, frequently induces severe off-target inflammatory toxicities. … To address this, we developed a nanoparticle-anchoring platform that selectively delivers CD137 agonists to the tumor tissue. … This localized retention leads to potent anti-cancer immunity without generating systemic toxicities, demonstrating a safer method for administering immune checkpoint agonists.”
For more technical references or data sheets regarding the Recombinant Anti-Mouse CD137 (4-1BB) Monoclonal Antibody (Clone: LOB12.3) formats, please contact our scientific support team at message@sydlabs.com.
Related Recombinant IgG Reference Antibodies:
Recombinant rat lgG1 isotype control antibody
Recombinant human IgG1 isotype control antibodies
Syd Labs provides the following anti-mouse 4-1BB antibodies:
Anti-mouse 4-1BB monoclonal antibody (Clone: 3H3)
Anti-mouse CD137 Antibody (LOB12.3) from: Anti-mouse CD137 (TNFRSF9 or 4-1BB) Monoclonal Antibody(Clone: LOB12.3): PA007275.r1 Syd Labs
